Electronic clinician notification alerts were shown to be effective in improving the timely evaluation & treatment of pts w/ severe #vhdAS or #vhdMR, according to the ALERT trial presented during a Featured Clinical Research session at #ACC26.

More: https://bit.ly/3NTwMVA #JACC #CardioSky

Cluster randomized trial: Automated ECN alerts improved timely guideline-directed evaluation & valve intervention for sig. AS & MR, supporting scalable EHR-based decision support to reduce undertreatment & improve access to valve care https://bit.ly/4ccYEND

#JACC #ACC26 #vhdAS #vhdMR #CardioSky

6 yrs after surgery or #TAVR with CoreValve/Evolut, low-risk AS pts showed no difference in all-cause mortality or disabling #stroke in the Evolut Low-Risk trial. However, reinterventions were higher after TAVR, largely driven by increased AR. https://bit.ly/4csz87C

#JACC #vhdAS #SAVR #CardioSky

🆕 PARTNER 3 findings show similar rates of death, #stroke or rehospitalization at 7 years among low-risk patients with severe, symptomatic #vhdAS who underwent either #TAVR or surgery. Valve durability and patient-reported outcomes similar.

Read more: https://bit.ly/3Wql8SU

#TCT2025

DapaTAVI Substudy: Does Dapagliflozin Improve Health Status Post TAVI? - American College of Cardiology

Dapagliflozin showed 🚫 no significant improvement in health status post-#TAVI in the DapaTAVI substudy. While it may reduce death or worsening #HeartFailure in pts with #vhdAS, further research of patients w/ residual symptoms is needed.

📰 Read the journal scan: https://bit.ly/47f7cB8

#CardioSky

Navitor valve showed favorable safety & performance at 30 days & 12 months in treating pts w/ symptomatic, severe AS who are at low or intermediate surgical risk, supporting its expanded use in low- & intermediate-risk pts https://bit.ly/4n4Bhs7

#JACCINT #ESCCongress #WCCardio #vhdAS #CardioSky

Combined TAVR and Ventricular Tachycardia Ablation for VT Storm With Severe Aortic Stenosis:

Combined #TAVR and VT ablation is feasible and can effectively treat 2 life-threatening problems in high-risk patients. A team-based, individualized approach is essential for procedural success. www.jacc.org/doi/10.1016/...

#JACCCaseReports #epAblation #vhdAS

Long-Term Outcomes of BAV-0 Patients Compared With BAV-1 and TAV Patients After TAVR:

Compared with TAVs and BAVs type 1 (BAV-1; 1 raphe), BAV type 0 (BAV-0; no raphe) was associated with a better long-term prognosis among patients with severe AS undergoing #TAVR procedures. www.jacc.org/doi/10.1016/... #JACCINT #vhdAS

Evolut Low Risk: Pts w/ severe #vhdAS who were treated w/ either #TAVR/surgery had comparable rates of all-cause mortality or disabling #stroke at 5️⃣ years. Valve durability & performance were also excellent in both groups. #ACC25

🔗 bit.ly/43wW1m7 #JACC @jaccjournals.bsky.social

#CardioSky #MedSky

In a late-breaking clinical trial, Dr. John Forrest from @yaleschoolofmed.bsky.social reports that low-risk patients with AS treated with #TAVR had similar rates of mortality and stroke at 5 years compared to those treated with surgery jacc.org/doi/10.1016/...

#JACC #ACC25 #vhdAS #SAVR #CardioSky

DAPA-TAVI: The #SGLT2 inhibitor dapagliflozin was superior to standard care alone in decreasing rates of all-cause mortality or worsening #HeartFailure in older adults w/ #vhdAS undergoing TAVI, resulting in a 28% relative risk ↘️. #ACC25

More: bit.ly/4cfLNsy

#cvSurg #CardioSky #MedSky